AMAG Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
AMAG AMAG Pharmaceuticals Inc
HCI Hci Group Inc
PSF Cohen & Steers Select Preferred and Income Fund
PJT PJT Partners Inc
ALK Alaska Air Group Inc
RS Reliance Steel & Aluminum Co
HFWA Heritage Financial Corp
MET MetLife Inc
KALU Kaiser Aluminum Corp
STBA S&T Bancorp Inc

Health Care : Biotechnology | Small Cap Value
Company profile

AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.

Closing Price
Day's Change
0.01 (0.07%)
B/A Size
Day's High
Day's Low

10-day average volume:

UPDATE: GE's stock gets a big boost after news that Boeing's 737 MAX could fly again this year

10:19 am ET October 17, 2020 (MarketWatch)

Tomi Kilgore

GE shares paced the S&P 500's gainers, to close at a 4-month high

Shares of General Electric Co. charged to a four-month high in active trading Friday, on growing hopes that Boeing Co.'s grounding 737 MAX planes will be able to fly again soon.

The industrial conglomerate's stock (GE) shot up 6.1% to $7,29, the highest close since June 16, and enough to make it the biggest gainer among the S&P 500 index's components. With trading volume of 167.9 million shares, the stock was the second-most active on the New York Stock Exchange.

European Union Aviation Safety Agency Executive Director Patrick Ky said in an interview with Bloomberg ( that the safety upgrades Boeing (BA) made to its MAX planes could mean they can return to European airspace by the end of the year (

The 737 MAX aircraft have been grounded since March 2019, following two deadly crashes within a five-month period.

GE's aerospace division, which makes engines featured in the 737 MAX aircraft, reported in July a second-quarter revenue decline of 44% from a year ago, making it by far the weakest of the company's major business segments. For the third quarter, the FactSet revenue consensus for GE Aviation of $4.93 billion implies a 39% decline.

Don't miss: GE's stock sinks, as CEO Culp can't call a bottom in the Aviation business (

Boeing's stock rose as much as 5.6% intraday before paring some gains to close up 1.9% at $167.35.

GE's stock has still dropped 34.7% year to date, while Boeing shares have shed 48.6% and the Dow Jones Industrial Average has gained 0.2%.

-Tomi Kilgore; 415-439-6400;

(END) Dow Jones Newswires

October 17, 2020 10:19 ET (14:19 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.